Shiga toxin a subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
The present invention provides Shiga toxin A Subunit derived polypeptides, scaffolds, and cell-targeting molecules comprising amino acid substitutions which equip the molecules with site-specific positions (and often unique amino acid residues in the molecule) for linking other molecules while retaining Shiga toxin function(s), such as, e.g., efficient intracellular routing and/or potent cytotoxicity. The present invention also provides cell-targeting molecules, and/or components thereof, which comprise site-specific positions for linking other molecules, such as, e.g., agents that alters a property of the cell-targeting molecule or a cargo for delivery. Certain molecules comprising a polypeptide of the present invention exhibit reduced immunogenicity and/or are well-tolerated by mammals. The cell-targeting molecules of the present invention, and compositions thereof, have uses, e.g., for the selective delivery of cargos to target-expressing cells and as diagnostic and/or therapeutic molecules for the treatment of a variety of diseases, disorders, and conditions, which include genetic disorders, genetic predispositions, infections, cancers, tumors, growth abnormalities, and/or immune disorders.
1. A Shiga toxin effector polypeptide comprising the amino acid sequence of SEQ ID NO: 828.
2. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
3. A method of treating cancer involving HER-2-expressing cells in a patient in need thereof, the method comprising the step of administering to the patient a therapeutically effective amount of the polypeptide of claim 1 .
4. A method of treating cancer involving HER-2-expressing cells in a patient in need thereof, the method comprising the step of administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 2 .
5. The method of claim 3 , wherein the cancer is selected from the group consisting of breast cancer, gastrointestinal cancer, and colorectal cancer.
6. The method of claim 4 , wherein the cancer is selected from the group consisting of breast cancer, gastrointestinal cancer, and colorectal cancer.
7. The method of claim 3 , wherein said administering is via intravenous administration.
8. The method of claim 4 , wherein said administering is via intravenous administration.
9. The method of claim 5 , wherein said administering is via intravenous administration.
10. The method of claim 6 , wherein said administering is via intravenous administration.